search
Back to results

A Safety and Acceptability Study of a Vaginal Ring Microbicide Delivery Method

Primary Purpose

HIV Infections

Status
Completed
Phase
Early Phase 1
Locations
International
Study Type
Interventional
Intervention
intravaginal ring
Sponsored by
International Partnership for Microbicides, Inc.
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional prevention trial for HIV Infections focused on measuring HIV-1, HIV seronegativity

Eligibility Criteria

18 Years - 35 Years (Adult)FemaleAccepts Healthy Volunteers

Inclusion Criteria:

  • Female, age 18-35 years
  • Willing and able to provide written informed consent
  • HIV-uninfected and otherwise healthy
  • Self-reported sexually active
  • On a stable hormonal contraceptive regimen
  • Regular menstrual cycle
  • Willing to refrain from use of vaginal products or objects during the study

Exclusion Criteria:

  • Currently pregnant or last pregnancy within 3 months prior to enrollment
  • Currently breast-feeding
  • Participated in any other research study within 30 days prior to enrollment;
  • Symptomatic untreated vaginal infections within 2 weeks prior to enrollment
  • Presence of abnormal physical finding on the vulva, vaginal walls or cervix
  • History of significant urogenital or uterine prolapse, undiagnosed vaginal bleeding, urethral obstruction;
  • Pap smear result at screening that requires cryotherapy, biopsy, treatment (other than for infection), or further evaluation
  • Unexplained, undiagnosed abnormal bleeding per vagina, bleeding per vagina during or following vaginal intercourse, or gynecologic surgery within 90 days prior to enrollment
  • Any serious acute, chronic or progressive disease

Sites / Locations

  • Reproductive Health & HIV Research Unit - Sheshisani IPM Clinic
  • South African Medical Research Council
  • Desmond Tutu HIV Foundation, Masiphumelele
  • Kilimanjaro Reproductive Health Program

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Experimental

Arm Label

A

B

Arm Description

vaginal ring first 12 weeks & observational safety last 12 weeks

observational safety first 12 weeks & vaginal ring last 12 weeks

Outcomes

Primary Outcome Measures

The primary measure of acceptability will be defined as the proportion of women indicating that they would use the study product if it is found to prevent HIV.
The primary measure of safety will be the proportion of women who have abnormal observations during the pelvic/speculum examinations and the proportion of women who experience adverse events

Secondary Outcome Measures

Full Information

First Posted
May 3, 2007
Last Updated
November 10, 2010
Sponsor
International Partnership for Microbicides, Inc.
search

1. Study Identification

Unique Protocol Identification Number
NCT00469170
Brief Title
A Safety and Acceptability Study of a Vaginal Ring Microbicide Delivery Method
Official Title
A Safety and Acceptability Study of a Vaginal Ring Microbicide Delivery Method for the Prevention of HIV Infection in Women
Study Type
Interventional

2. Study Status

Record Verification Date
November 2010
Overall Recruitment Status
Completed
Study Start Date
March 2007 (undefined)
Primary Completion Date
February 2010 (Actual)
Study Completion Date
February 2010 (Actual)

3. Sponsor/Collaborators

Name of the Sponsor
International Partnership for Microbicides, Inc.

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
The proposed study is a multi-centre, open-label crossover study to assess the safety and acceptability of a silicone elastomer vaginal ring (containing no drug) when inserted for a 12 week period in 200 healthy, sexually active women.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
HIV Infections
Keywords
HIV-1, HIV seronegativity

7. Study Design

Primary Purpose
Prevention
Study Phase
Early Phase 1
Interventional Study Model
Crossover Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
220 (Actual)

8. Arms, Groups, and Interventions

Arm Title
A
Arm Type
Experimental
Arm Description
vaginal ring first 12 weeks & observational safety last 12 weeks
Arm Title
B
Arm Type
Experimental
Arm Description
observational safety first 12 weeks & vaginal ring last 12 weeks
Intervention Type
Device
Intervention Name(s)
intravaginal ring
Intervention Description
silicone elastomer intravaginal ring containing no drug product
Primary Outcome Measure Information:
Title
The primary measure of acceptability will be defined as the proportion of women indicating that they would use the study product if it is found to prevent HIV.
Time Frame
3 months
Title
The primary measure of safety will be the proportion of women who have abnormal observations during the pelvic/speculum examinations and the proportion of women who experience adverse events
Time Frame
3 months

10. Eligibility

Sex
Female
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
35 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Female, age 18-35 years Willing and able to provide written informed consent HIV-uninfected and otherwise healthy Self-reported sexually active On a stable hormonal contraceptive regimen Regular menstrual cycle Willing to refrain from use of vaginal products or objects during the study Exclusion Criteria: Currently pregnant or last pregnancy within 3 months prior to enrollment Currently breast-feeding Participated in any other research study within 30 days prior to enrollment; Symptomatic untreated vaginal infections within 2 weeks prior to enrollment Presence of abnormal physical finding on the vulva, vaginal walls or cervix History of significant urogenital or uterine prolapse, undiagnosed vaginal bleeding, urethral obstruction; Pap smear result at screening that requires cryotherapy, biopsy, treatment (other than for infection), or further evaluation Unexplained, undiagnosed abnormal bleeding per vagina, bleeding per vagina during or following vaginal intercourse, or gynecologic surgery within 90 days prior to enrollment Any serious acute, chronic or progressive disease
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Dr. Annalene Nel
Organizational Affiliation
IPM
Official's Role
Study Director
Facility Information:
Facility Name
Reproductive Health & HIV Research Unit - Sheshisani IPM Clinic
City
Yeoville
State/Province
Johannesburg
Country
South Africa
Facility Name
South African Medical Research Council
City
Durban
State/Province
KwaZulu Natal
ZIP/Postal Code
4067
Country
South Africa
Facility Name
Desmond Tutu HIV Foundation, Masiphumelele
City
Cape Town
ZIP/Postal Code
7975
Country
South Africa
Facility Name
Kilimanjaro Reproductive Health Program
City
Moshi
Country
Tanzania

12. IPD Sharing Statement

Learn more about this trial

A Safety and Acceptability Study of a Vaginal Ring Microbicide Delivery Method

We'll reach out to this number within 24 hrs